Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 plus pembrolizumab in anti-PD-1 refractory melanoma
NCT04570332Phase 2Completed
- Sponsor
- Highlight Therapeutics
- Start
- Dec 2020
- Primary completion
- Oct 2023
- Modality
- Oncolytic Viruses, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of nanoplexed poly I:C in melanoma, sponsored by Highlight Therapeutics. Started Dec 2020; status: completed.
02
Drugs
nanoplexed poly I:C
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04570332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570332.